China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-29	US$2.440	-3.17%	22,533
26-09-28	US$2.520	-1.95%	42,195
26-09-25	US$2.570	+0.78%	18,173
26-09-24	US$2.550	+1.59%	41,785
26-09-23	US$2.510	+1.62%	75,240

Delayed Quote Nasdaq

More quotes

Real-time Estimate Cboe BZX 10:24:18 2026-09-29 EDT			5-day change	1st Jan Change
2.505 ^USD	-0.60%		-1.21%	-99.99%

08-05	Top Premarket Decliners	MT
07-30	Top Premarket Gainers	MT

Market Cap	3.33M 2.93M 2.77M 2.51M 4.72M 320M 4.74M 33.16M 12.81M 163M 12.5M 12.23M 524M	P/E 2025 *	-	P/E 2026	-
Enterprise Value	-23.87M -20.99M -19.85M -18.01M -33.82M -2.29B -34.01M -238M -91.8M -1.17B -89.62M -87.68M -3.76B	EV / Sales 2025	9.8x	EV / Sales 2026	-22.6x
Free-Float	66.63%	Yield 2025 *	-	Yield 2026	-

Markets		Quality
Nasdaq	SXTC	Delayed
CBOE	SXTC	Real-time
Deutsche Boerse AG	2RY2	Delayed
Tradegate	2RY2	Real-time

08-05	Top Premarket Decliners	MT
07-30	Top Premarket Gainers	MT
07-28	Top Premarket Decliners	MT
07-24	Top Premarket Decliners	MT
07-23	Top Premarket Decliners	MT
07-22	Top Premarket Gainers	MT
07-02	China SXT Pharmaceuticals, Inc. announced that it expects to receive $28.56 million in funding	CI
07-01	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
01-08	Top Midday Gainers	MT
12-31	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2025	CI
25-07-31	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2025	CI
25-03-28	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2024	CI
25-03-17	China Sxt Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Requirement	MT

China SXT Pharmaceuticals, Inc. Stock

Stocks

SXTC

VGG2161P1734

Pharmaceuticals

Valuation: China SXT Pharmaceuticals, Inc.

Chart: China SXT Pharmaceuticals, Inc.

Latest news: China SXT Pharmaceuticals, Inc.

Analysts' recommendations: China SXT Pharmaceuticals, Inc.

Press Releases: China SXT Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: China SXT Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 day	-0.60%
1 week	-1.21%
Current month	-4.69%
1 month	-4.69%
3 months	-98.50%
6 months	-98.15%
Current year	-99.99%

1 week	2.35	2.74
1 month	1.78	3.05
Current year	1.78	83,758.33
1 year	1.78	83,758.33
3 years	1.78	613,438.04
5 years	1.78	67,307,692.31
10 years	1.78	4,490,384,615.38

Manager	Title	Age	Since
Sze Beng Lim CEO	Chief Executive Officer	-	2025-01-19
Feng Zhou CEO	Chief Executive Officer	34	2017-07-03
Xiaodong Pan DFI	Director of Finance/CFO	49	2022-01-30

Director	Title	Age	Since
Feng Zhou CHM	Chairman	34	2017-07-03
Jun Zheng BRD	Director/Board Member	49	2018-12-30
Xiaodong Ji BRD	Director/Board Member	57	2021-05-21

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA SXT PHARMACEUTICALS, INC.	-0.60%	-1.21%	-99.99%	-100.00%	3.33M
ELI LILLY AND COMPANY	-0.87%	+1.00%	+62.67%	+120.03%	1,056B
JOHNSON & JOHNSON	-2.07%	-0.57%	+47.37%	+71.85%	655B
ABBVIE INC.	-1.36%	-0.29%	+18.50%	+77.41%	471B
ROCHE HOLDING AG	-1.79%	-3.71%	+36.90%	+39.99%	342B
NOVARTIS AG	-0.65%	+4.02%	+22.30%	+29.05%	277B
ASTRAZENECA PLC	-0.74%	-1.61%	+12.45%	+12.30%	257B
AMGEN INC.	-0.52%	+2.13%	+52.93%	+55.89%	226B
GILEAD SCIENCES, INC.	-1.62%	-1.03%	+34.16%	+101.62%	189B
NOVO NORDISK A/S	-0.41%	-2.63%	-28.31%	-60.86%	170B
Average	-1.03%	+1.46%	+15.90%	+34.73%	364.29B
Weighted average by Cap.	-1.20%	+1.04%	+38.86%	+70.46%

	2025	2026
Net sales	1.74M 1.53M 1.45M 1.31M 2.47M 167M 2.48M 17.34M 6.7M 85.27M 6.54M 6.39M 274M	1.14M 1M 946K 858K 1.61M 109M 1.62M 11.33M 4.38M 55.74M 4.27M 4.18M 179M
Net income	-3.3M -2.91M -2.75M -2.49M -4.68M -317M -4.71M -32.9M -12.71M -162M -12.4M -12.13M -520M	-6.21M -5.46M -5.16M -4.68M -8.79M -596M -8.84M -61.79M -23.86M -304M -23.3M -22.79M -977M
Net Debt	-17.25M -15.17M -14.35M -13.01M -24.44M -1.66B -24.58M -172M -66.35M -845M -64.77M -63.37M -2.72B	-27.2M -23.92M -22.62M -20.52M -38.53M -2.61B -38.76M -271M -105M -1.33B -102M -99.91M -4.28B